Shareholders of Apotea AB (publ) (STO:APOTEA) will be pleased this week, given that the stock price is up 13% to kr104 following its latest third-quarter results. It looks like a credible result overall - although revenues of kr2.0b were in line with what the analysts predicted, Apotea surprised by delivering a statutory profit of kr0.79 per share, a notable 11% above expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the consensus forecast from Apotea's twin analysts is for revenues of kr9.13b in 2027. This reflects a notable 17% improvement in revenue compared to the last 12 months. Per-share earnings are expected to surge 41% to kr3.52. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr9.13b and earnings per share (EPS) of kr3.52 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
View our latest analysis for Apotea
With the analysts reconfirming their revenue and earnings forecasts, it's surprising to see that the price target rose 6.5% to kr98.50. It looks as though they previously had some doubts over whether the business would live up to their expectations.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Apotea's past performance and to peers in the same industry. The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 13% growth on an annualised basis. That is in line with its 11% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 3.9% per year. So although Apotea is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have analyst estimates for Apotea going out as far as 2028, and you can see them free on our platform here.
You can also see our analysis of Apotea's Board and CEO remuneration and experience, and whether company insiders have been buying stock.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.